Quantitative Systematic Strategies LLC acquired a new stake in Humana Inc. (NYSE:HUM) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,807 shares of the insurance provider’s stock, valued at approximately $2,571,000. Humana accounts for about 0.5% of Quantitative Systematic Strategies LLC’s portfolio, making the stock its 12th largest holding.
A number of other institutional investors have also recently made changes to their positions in the business. BlackRock Inc. grew its stake in Humana by 3.2% in the first quarter. BlackRock Inc. now owns 12,352,180 shares of the insurance provider’s stock valued at $5,178,651,000 after acquiring an additional 385,141 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Humana by 1.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,089,140 shares of the insurance provider’s stock valued at $4,229,872,000 after acquiring an additional 99,832 shares during the period. Janus Henderson Group PLC grew its stake in Humana by 2.6% in the first quarter. Janus Henderson Group PLC now owns 1,875,237 shares of the insurance provider’s stock valued at $786,294,000 after acquiring an additional 46,973 shares during the period. Ameriprise Financial Inc. grew its stake in Humana by 7.8% in the first quarter. Ameriprise Financial Inc. now owns 1,261,640 shares of the insurance provider’s stock valued at $528,961,000 after acquiring an additional 91,169 shares during the period. Finally, Diamond Hill Capital Management Inc. lifted its holdings in shares of Humana by 1.1% in the second quarter. Diamond Hill Capital Management Inc. now owns 1,137,274 shares of the insurance provider’s stock valued at $503,494,000 after purchasing an additional 12,361 shares in the last quarter. 91.85% of the stock is owned by hedge funds and other institutional investors.
In other Humana news, Director David A. Jr/Ky Jones sold 4,800 shares of Humana stock in a transaction dated Thursday, September 16th. The stock was sold at an average price of $401.00, for a total transaction of $1,924,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.40% of the company’s stock.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, July 28th. The insurance provider reported $6.89 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $6.86 by $0.03. Humana had a return on equity of 13.62% and a net margin of 3.09%. The firm had revenue of $20.65 billion during the quarter, compared to analyst estimates of $20.51 billion. As a group, sell-side analysts expect that Humana Inc. will post 21.49 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, October 29th. Shareholders of record on Thursday, September 30th will be paid a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a yield of 0.69%. The ex-dividend date is Wednesday, September 29th. Humana’s dividend payout ratio (DPR) is currently 14.93%.
HUM has been the topic of a number of recent analyst reports. Seaport Res Ptn reiterated a “neutral” rating on shares of Humana in a report on Friday, July 9th. Barclays initiated coverage on Humana in a report on Thursday, September 9th. They set an “overweight” rating and a $500.00 price target on the stock. Wells Fargo & Company initiated coverage on Humana in a report on Monday, May 24th. They set an “equal weight” rating and a $472.00 price target on the stock. Seaport Global Securities initiated coverage on Humana in a report on Friday, July 9th. They set a “neutral” rating and a $455.65 price target on the stock. Finally, Morgan Stanley lifted their price target on Humana from $500.00 to $513.00 and gave the stock an “overweight” rating in a report on Tuesday, August 31st. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $485.63.
Humana Inc engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental benefit plans such as Medicare, and State-based Medicaid contracts.
Featured Story: Is it Safe to Invest in Commodities?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.